Nonalcoholic fatty liver disease in the pediatric population: A review

Current Opinion in Pediatrics

Volumn 17, Issue 5, 2005, Pages 636-641

  Wieckowska, Anna ^a   Feldstein, Ariel E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Disease; Fatty; Liver; Nonalcoholic; Nonalcoholic steatohepatitis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; BETAINE; GLUCOSE; INSULIN; METFORMIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID;

AMINOTRANSFERASE BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG EFFECT; ECHOGRAPHY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; LABORATORY TEST; LIFESTYLE; LIVER BIOPSY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; WEIGHT REDUCTION;

ADOLESCENT; CHILD; FATTY LIVER; HUMANS;

EID: 26044439697     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000172816.79637.c5     Document Type: Review

References (68)

1. Moran JR, Ghishan FK, Halter SA, et al. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol 1983; 78:374-377.
2. Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver disease in Japanese children and relation to obesity: an epidemiological sonographic survey. Dig Dis Sci 1995; 40:2002-2009.
3. Kahen T, Schwimmer J, Lavine J, et al. Population prevalence of pediatric fatty liver disease. Gastroenterology 2004; 126:T1093.
4. Schwimmer JB, McGreal N, Deutsch R, et al. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 2005; 115: e561-e565.
5. Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997; 42:1428-1432.
6. Chan DF, Li AM, Chu WC, et al. Hepatic steatosis in obese Chinese children. Int J Obes Relat Metal Disord 2004; 28:1257-1263.
7. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents. JAMA 2002; 288: 1728-1732.
8. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350:2362-2374. This study of 439 obese and 31 overweight children shows that the prevalence of metabolic syndrome reaches 50% in severely obese youngsters.
9. Lavine JE, Schwimmer JB. Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis 2004; 8:549-558. This complete review on pediatric NAFLD highlights the differences between pediatric and adult patients.
10. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, et al. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995; 127: 700-704.
11. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30:48-53.
12. Schwimmer JB, Deutsch R, Rauch JB, et al. Obesity, insulin resistance, and other clinicopathological correlations of pediatric nonalcoholic fatty liver disease. J Pediatr 2003; 143:500-505.
13. Fishbein MH, Miner M, Mogren C, Chalekson J. The spectrum of fatty liver in obese children and the relationship of serum aminotransferases to severity of steatosis. J Pediatr Gastroenterol Nutr 2003; 36:54-61.
14. Tazawa Y, Noguchi H, Nishinomiya F, Takada G. Serum alanine aminotransferase activity in obese children. Acta Paediatr 1997; 86:238-241.
15. Mathiesen UL, Franzen LE, Aselius H, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002; 34:516-522.
16. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462-E468.
17. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123:745-750.
18. Brunt EM, Tiniakos DG. Pathological features of NASH. Front Biosci 2005; 10:1475-1484. The is the latest review of different histological features of NASH and their significance.
19. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467-2474.
20. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histologic scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321. New scoring system for fatty liver to be used in research studies.
21. Day C, Saksena S. Non-alcoholic steatohepatitis: Definition and pathogenesis. J Gastroenterol Hepatol 2002; 17:8377-8384.
22. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107:450-455.
23. Hui JH, Hodge A, Farrell GC, et al. Beyond Insulin Resistance in NASH: TNF-alpha or Adiponectin? Hepatology 2004; 40:46-54. In this study, reduced adiponectin level was associated with more extensive necroinflammation but not with fibrosis in adults with NAFLD.
24. Takayuki M, Seiichi C, Hiroshi T, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-α in KK-Ay obese mice. Hepatology 2004; 40:177-184. This experimental study suggested that exogenous adiponectin treatment might prevent liver injury by blocking TNF-alpha pathway in obese mice.
25. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathway. Hepatology 2004; 40:185-194. Free fatty acids may directly induce TNF-alpha expression in hepatocytes in a process involving lysosomal permeabilization.
26. Feldstein AE, Gores GJ. Steatohepatitis and apoptosis: Therapeutic implications. Am J Gastroenterol 2004; 99:1718-1719.
27. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 2005; 1:3093-3099.
28. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125:437-443.
29. Ribeiro PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99:1708-1717.
30. Feldstein AE, Canbay A, Guicciardi ME, et al. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 2003; 39:978-983.
31. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
32. Schwimmer JB, Deutsch R, Rauch JB, et al. Obesity, insulin resistance, and other clinicopathological correlations of pediatric nonalcoholic fatty liver disease. J Pediatr 2003; 143:500-505.
33. Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53:750-755. This large cohort study demonstrates that patients with a simple steatosis without inflammation had the same life expectancy as the general population and minimal risk of progression to cirrhosis.
34. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population based cohort study. Gastroenterology. 2005; 129: 113-121. This large population-based study on the natural history of NAFLD demonstrates a significant increase in morbidity and overall and liver-related mortality as compared to the general population.
35. Feldstein AE;, El-Youssef M, Freese DK, Lindor KD, Angulo P. Nonalcoholic fatty liver disease in children: A follow-up study for up to 16 years. Gastroenterology 2003; 124:A701.
36. Molleston JP, White F, Teckman J, Fitzgerald JF. Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol 2002; 97: 2460-2462.
37. Kerkar N. Non alcoholic steatohepatitis in children. Pediatr Transpl 2004; 8: 613-618.
38. Charlton M, Kasparova P, Weston S, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001; 7:608-614.
39. Jonas MM, Krawczuk LE, Kim HB, et al. Rapid recurrence of nonalcoholic fatty liver disease after transplantation in a child with hypopituitarism and hepatopulmonary syndrome. Liver Transpl 2005; 11:108-110.
40. Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004; 39:909-914.
41. Cuadrado A, Orive A, Garcia-Suarez C, et al. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg 2005; 15:442-446.
42. Schwimmer JB, Burwinkle TM, Varni JW. Health-related quality of life of severely obese children and adolescents. JAMA 2003; 289:1813-1819.
43. Angulo P. Current best treatment for non-alcoholic fatty liver disease. Expert Opin Pharmacother 2003; 4:611-623.
44. Harrison SA, Neuschwander-Tetri BA. Pharmacologic management of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8:715-728.
45. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39:1647-1654.
46. Park HS, Kim MW, Shin ES. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci 1995; 10:414-421.
47. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27:103-107.
48. Vajro P, Fontanella A, Perna C, et al. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994; 125:239-241.
49. Rozental P, Biava C, Spencer H, Zimmerman HJ. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967; 12: 198-208.
50. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12:224-229.
51. Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Metab 2002; 16:703-716.
52. Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005; 50:171-180.
53. Bugianesi E, Gentilcore E, Manini R, et al. A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2005; 100:1082-1090.
54. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358:893-894.
55. Schwimmer JB, Middleton MS, Deutsch R, Lavine JE. Metformin as a treatment for non-diabetic NASH. J Pediatr Gastroenterol Nutr 2003; 37:342.
56. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136:734-738.
57. Hasegawa T, Yoneda M, Nakamura K, et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ther 2001; 15:1667-1672.
58. Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98:2348-2350.
59. Guma G, Viola L, Thome M, et al. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: results of a prospective controlled clinical trial. Hepatology 1997; 26:386A.
60. Ceriani R, Bunati S, Morini L, et al. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis. Hepatology 1998; 28:386.
61. Laurin J, Lindnor K, Clippin J, et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol induced steatohepatitis: a pilot study. Hepatology 1996; 23:1464-1467.
62. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39:770-778. This large, randomized placebo-controlled trial showed no benefits from ursodeoxycholic acid as compared to placebo.
63. Vajro P, Franzese A, Valerio G, et al. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000; 136: 739-743.
64. Abdelmalek MF, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96:2711-2717.
65. Miglio F, Rovati LC, Santoro A, Setnikar I. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung 2000; 50:722-727.
66. Gülbahar O, Karasu ZA, Ersöz G, et al. Treatment nonalcoholic steatohepatitis with N-acetylcysteine. Gastroenterology 2000; 118:A1444.
67. Pamuk GE, Sonsuz A. N-acetylcysteine in the treatment of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2003; 18:1220-1221.
68. Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management. Clin Biochem 2005; 38:203-217.